National Center for Geriatrics and Gerontology Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting and disabling side effect with no proven effective treatment or prevention. Therefore, we aimed to evaluate the effectiveness of frozen glove and sock (FGS) in preventing CIPN with multiple assessments. Methods: Forty breast cancer patients treated weekly with paclitaxel (80 mg/m 2 for 1 h) wore FGS on the dominant hand and foot for 90 min, including the entire duration of drug infusion. Signs and symptoms on the treated sides were compared to the untreated (nondominant) sides. Primary endpoint was CIPN incidence as assessed by tactile sensitivity change from pretreatment baseline in monofilament test at a cumulative dose of 960 mg/m 2 (12 administrations). We also assessed thermosensory deficits, subjective symptoms (Patient Neuropathy Questionnaire (PNQ)), manipulative dexterity, and the cumulative dose-subjective events association. McNemar's test (tactile, thermal, and PNQ), log-rank test (cumulative dose-event relation), and paired t-test (dexterity) were used for statistical comparisons. Results: Among the 40 patients enrolled, 4 did not reach the cumulative dose due to pneumonia, severe fatigue, severe liver dysfunction, or macular edema, leaving 36 patients for primary endpoint analysis. None dropped out because of cold intolerance. Incidence of both objective and subjective CIPN signs was significantly lower on the intervention side than on the control (primary outcome, hand: 28% vs. 81%, foot: 25% vs. 64%; warm-sense: hand, 9% vs. 32%, foot, 33% vs. 57%; PNQ: hand, 3% vs. 42%, foot, 3% vs. 36%; hazard ratio: hand, 0.126, foot, 0.131). Deterioration of hand dexterity was also significantly prevented by FGS (mean delay, -2.5 vs. 8.6 s). Conclusions: FGS is useful in mitigating the objective and subjective symptoms of CIPN and its resultant dysfunction. These findings indicate the clinical applicability of the program. Purpose: Cancer-related fatigue is one of the most prevalent symptoms that patients with cancer experience. We aimed to quantify and mechanistically evaluate the improvement in fatigue related to administration of the Kampo medicine. Experimental Design: Initially, we compared fatigue levels of 37 patients with cancer to a control group of 23 volunteers who had recovered completely from cancer. Fatigue level was estimated by using an autonomic function analyzer. Next, Kamikihito was administered to another 35 patients treated with hormone or antitumor therapy for prostate cancer and with a molecular-targeted drug for metastatic renal cell cancer. Patient fatigue was assessed using a visual analogue fatigue scale, fatigue scale, depression scale and sleepiness scales. Serum levels of derivatives of reactive oxygen species (an index of oxidative stress) and biological antioxidant potential (an index of anti-oxidative activity) were also measured. Results: Patients in the cancer treatment group experienced more fatigue compared to the control patients when evaluated by using autonomic function analyzer. The group of 35 patients who were administered Kamikihito showed improved scores for fatigue, depression, and sleepiness; however, visual analogue scale score or Pittsburgh index did not change. Autonomic nervous system balance evaluated by using the autonomic nerve analyzer was also improved with Kamikihito administration. The Kamikihito group also had significantly lower reactive metabolite levels and significantly higher antioxidant potential. Conclusions: Fatigue was more serious in patients with cancer than in control patients. Kamikihito rescued this fatigue and improved anxiety and sleepiness. It restored autonomic nervous system balance and antioxidant function. Background: Some anticancer drugs have different safety profiles by race, such as myelo-suppression and interstitial lung disease. There is a clinical need to confirm the safety profile of anti-PD1 drugs for Japanese patients. Methods: The dataset for this combined analysis included Japanese patients who participated in a Japanese phase 1 trial for solid tumors (KEYNOTE-011 part A), a Japanese phase 1b trial for non-small cell lung cancer (NSCLC) (KEYNOTE-025), an international phase 2/3 for NSCLC (KEYNOTE-010) and a Japanese phase 1b trial for melanoma (KEYNOTE-041). We analyzed the incidence of adverse events among patients who received at least one cycle of pembrolizumab. Results: The numbers of Japanese patients who received pembrolizumab monotherapy were 10 in KEYNOTE-011 part A, 38 in KEYNOTE-025, 62 in KEYNOTE-010, and 42 in KEYNOTE-041, including 105 NSCLC and 45 melanoma patients. Among the total of 152 Japanese patients, any drug-related adverse events occurred in 127 (84%) patients, whereas Grade > ¼3 drug-related adverse events in 31 (20%) patients and drug-related deaths in 3 (0.2%) patients were observed. Among the total of 2799 patients from 4 global trials for melanoma or NSCLC (KEYNOTE-001, 002, 006, 010), any drug-related adverse events occurred in 2727 (97.4%) patients, whereas Grade > ¼3 drug-related adverse events occurred in 386 (13.8%) patients and drugrelated deaths were observed in 10 (0.4%) patients. In overall population and Japanese patients who received pembrolizumab in KEYNOTE-010, Grade > ¼3 drug-related adverse events occurred in 98 (14%) and 14 (22%) patients, any immune-mediated adverse events occurred in 133 (20%) and 15 (24%), Grade > ¼3 immune-mediated adverse events occurred in 36 (5.3%) and 8 (13%), and pneumonitis in 31 (4.5%) and 3 (4.8%) patients, respectively. Conclusion: The safety profile of pembrolizumab in Japanese patients did not show clinically meaningful differences compared to non-Japanese patients.
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Introduction: Anti PD-1 antibody, nivolumab, is associated with a spectrum of immune-related adverse events including cardiotoxicity. We report two patients who developed myocarditis and pericarditis during treatment with nivolumab. Case reports: Patient 1; A 71-year-old man who has lung adenocarcinoma. He received 2 cycles of nivolumab as 2nd line chemotherapy. After 32 days from first cycle, he was admitted to our hospital with anorexia. The troponin I level increased to 400 pg/ml and ECG showed ST segment elevation in leads V2-V6. No significant stenosis was showed in coronary angiography. Myocardial biopsy revealed only myocardial hypertrophy and replacement fibrosis. A diagnosis of myocarditis caused by nivolumab was made, he was treated with hydrocortisone and his symptom and ST segment elevation of ECG were improved. Patient 2; A 76-year-old man who has lung squamous cell carcinoma as postoperative recurrence. After 4 cycles of nivolumab, he developed pruritus and anorexia that was responsive to 20mg prednisolone. Although receiving 20mg prednisolone, he was admitted to our hospital with chest tightness and dyspnea after 168 days from first cycle. ECG showed ST segment elevation and echocardiography showed pericardial effusion. Coronary angiography revealed normal and troponin I was negative. A diagnosis of nivolumab induced pericarditis was made and the dose of prednisolone was increased to 50mg. His symptom and ST segment elevation of ECG was improved. Discussion: Although there has been reported only a few cases of myocarditis caused by immune checkpoint inhibitors, a possibility of underestimation may exist because myocarditis shows non-specific symptoms in early phase such as anorexia and fatigue. In our cases, definitive diagnoses could be made by intensive cardiac examination. We suggest ECG monitoring, echocardiography, and cardiac enzyme examination should be considered even if it is negligible symptoms during immune checkpoint inhibitor treatment. 
